Neobe raises $6.8M seed to help cancer drugs break through tumour walls
What's the deal? UK biotech Neobe TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised a £5 million ($6.8 million) seed round to develop engineered bacteria that break down the physical barriers stopping cancer drugs from reaching solid tumours. ARC VenturesDealroom has a profile for this one. Try Dealroom → led, with FaberDealroom has a profile for this one. Try Dealroom →, Macmillan VenturesDealroom has a profile for this one. Try Dealroom →, Proven Connect, Empirical VenturesDealroom has a profile for this one. Try Dealroom →, and returning pre-seed backer 2048 Ventures taking part.
What's the endgame? Many immunotherapies fail for a physical reason: a dense, fibrous matrix walls off the tumour, blocking immune cells and drugs. Neobe engineers harmless bacteria into living medicines that travel to tumours and release enzymes to dissolve that wall, letting treatments in.
The proof so far: In a 2026 paper in Molecular Cancer Therapeutics , Neobe — working with the University of Cyprus and London's Barts Cancer Institute — tested its platform on a triple-negative breast cancer model that had resisted a standard immunotherapy cocktail. A single dose produced complete tumour regression in one model, with no relapse months later.
Where the money goes: The funding takes lead programme NEO22 through preclinical studies toward an investigational-new-drug filing in 2028. That brings total funding to more than $10.5 million (£7.9 million), following a 2024 financing.
The new hire: Neobe has appointed immuno-oncology specialist Laura Chow as chief medical officer to oversee clinical development toward a first-in-human trial, which an additional tranche of the current seed round will fund.
Why now? "Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed," said co-founder and chief executive officer Pedro Correa de Sampaio. The round is a meaningful step-up for a still-preclinical company.
What could go wrong? The approach remains unproven in people. Its significance rests on whether Neobe can show safety and efficacy in studies leading to clinical testing — and a first-in-human trial is still years off.
The signal: The round sits in the top 5% of all UK seed rounds in health by size, a vote of confidence in engineered bacteria as a route around immunotherapy resistance. Other programmes in the field are drawing support too, including a $13.1 million NIH award in 2026.
Read more: finanznachrichten.de
Image credit: History at NIH